We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor- (TGF- ).
Negative free cash flow of -$129M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$113M
▲ +29.0% YoY
Op. Margin
—
ROIC
-39.87%
▼ -0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$99M
▲ +19.2% YoY
Op. Cash Flow (TTM)
-$99M
▲ +17.5% YoY
Net Debt
-$142M
Net Cash Position
Cash & Equiv.
$171M
Continue Research